13F Data
13F filer · CIK 1687078

MPM BIOIMPACT LLC

BOSTON, MA · filing since Q4 2019 · last filing Aug 14, 2026
Reported value
$1.6B
+$345.1M vs prior
Positions
37
New / sold out
7 / 11
Added / reduced
7 / 22
Turnover
19.7%
buys $289.8M · sells $335.2M
Top-10 weight
55.3%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewUltragenyx Pharmaceuticals, Inc.+1,418,215–+$47.4M
NewBIOAGE Labs Inc+1,667,661–+$40.9M
AddedCullinan Therapeutics, Inc.+2,083,073+27.2%+$37.9M
NewTaysha Gene Therapies, Inc.+4,500,000–+$30.6M
AddedAbivax SA+229,079+213.6%+$30.5M
NewZura Bio Ltd.+4,472,843–+$26.4M
NewAdlai Nortye Ltd+1,936,291–+$22.3M
NewAnnexon Inc+3,544,354–+$20.2M
AddedDyne Therapeutics, Inc.+513,941+36.5%+$11.4M
NewEntrada Therapeutics, Inc.+1,253,053–+$9.2M
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outAgios Pharmaceuticals Inc-1,306,261-100.0%$-44.2M
Sold outXenon Pharmaceuticals Inc-588,706-100.0%$-34.2M
Sold outEvommune Inc-1,455,863-100.0%$-33.5M
Sold outCytokinetics Inc-500,000-100.0%$-33.0M
ReducedDBV Technologies S A-1,547,077-29.7%$-25.4M
Sold outCorvus Pharmaceuticals Inc-1,674,875-100.0%$-24.5M
ReducedCorcept Therapeutics, Inc.-214,672-21.8%$-18.7M
Sold outClimb Bio Inc-2,593,439-100.0%$-17.8M
Sold outArcutis Biotherapeutics Inc-733,966-100.0%$-17.3M
Sold outZymeworks, Inc.-565,249-100.0%$-14.2M
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2019: $282.2MQ1 2020: $163.7MQ2 2020: $376.1MQ3 2020: $415.1MQ4 2020: $588.5MQ1 2021: $795.9MQ2 2021: $608.7MQ3 2021: $644.7MQ4 2021: $548.5MQ1 2022: $372.6MQ2 2022: $360.0MQ3 2022: $422.2MQ4 2022: $385.5MQ1 2023: $384.9MQ2 2023: $496.6MQ3 2023: $374.6MQ4 2023: $427.4MQ1 2024: $622.0MQ2 2024: $643.5MQ3 2024: $666.6MQ4 2024: $704.4MQ1 2025: $581.7MQ2 2025: $577.2MQ3 2025: $610.9MQ4 2025: $874.0MQ1 2026: $1.3BQ2 2026: $1.6B
Q4 2019Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Cullinan Therapeutics, Inc.2300311069,731,341$177.2M10.81%
2Aktis Oncology, Inc.01021M1044,835,872$155.9M9.50%
3Liquidia Corporation53635D2021,386,174$110.5M6.74%
4Revolution Medicines, Inc.76155X100492,483$92.2M5.62%
5Corcept Therapeutics, Inc.218352102771,028$67.0M4.09%
6Edgewise Therapeutics Inc28036F1051,620,780$65.9M4.02%
7Travere Therapeutics Inc89422G1071,122,731$63.8M3.89%
8DBV Technologies S A23306J3093,666,284$60.1M3.67%
9Trevi Therapeutics Inc89532M1013,073,577$57.3M3.50%
10Alumis Inc0223071022,019,020$56.8M3.46%
27 more rows. Subscribe for $29/month to see every row, download the data and use the API.